Q32 Bio Inc.
A maker of biologic medicines that calm an overactive immune system, Q32 Bio develops antibody treatments for autoimmune and inflammatory diseases. Its lead drug candidate, bempikibart, is being studied for alopecia areata, an autoimmune condition that causes hair loss. The Waltham, Massachusetts company began in 2017 as AdMIRx and renamed itself Q32 Bio in 2020 — a name it has never publicly explained.
Bought 1.88M
Bought 1.88M
Sold 9.8K
Sold 2.8K
Sold 4.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Orbimed Advisors LLC +2 co-filersDirector, 10% owner · 2 transactions | — | 4.13M | — | 1.88M | — |
| Xu DiyongDirector, 10% owner · 2 transactions | — | 4.13M | — | 1.88M | — |
| Morrison Jodie PopeCEO, Director · 1 transaction | +285.2% | 343.3K | — | — | 9.8K |
| Violette Shelia M.Chief Scientific Officer · 1 transaction | +78.6% | 164.0K | — | — | 2.8K |
| Kalowski LeeCFO and President · 1 transaction | +285.3% | 138.5K | — | — | 4.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: +3.73M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.